NDA 022192 · Vanda Pharms INC
Fanapt
Iloperidone · Oral · Atypical Antipsychotic
NovelLast checked: Nov 19, 2026Latest source record: Jan 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
May 6, 2009
Approved uses
3
Original approval plus efficacy supplements
Registered trials
27
5 Phase 3, 3 recruiting
FAERS reports
1,476
722 serious, 60 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. FANAPT is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. FANAPT is not approved for use in patients with dementia-related psychosis. ( 5.1 )
What it is approved for
From the label in effect May 6, 2026.
FANAPT ® is indicated for: Treatment of schizophrenia in adults [see Clinical Studies (14.1) ]. Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies (14.2) ] . FANAPT is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults. ( 1 , 14.1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. ( 1 , 14.2 )
Mechanism: The mechanism of action of iloperidone in schizophrenia and bipolar I disorder is unknown. However, the efficacy of iloperidone could be mediated through a combination of dopamine type 2 (D 2 ) and serotonin type 2 (5-HT 2 ) antagonism. Iloperidone forms an active metabolite, P88, that has an in vitro receptor binding profile similar to the parent drug.
Therapeutic areas: Psychiatry
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 2, 2024 Supplement 23 · Efficacy LabelLetter
- May 26, 2016 Supplement 15 · Efficacy LabelLetter
- May 6, 2009 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
7 products under this application
- FANAPT · ILOPERIDONE 12MG · TABLET, ORAL · Prescription · TE AB
- FANAPT · ILOPERIDONE 8MG · TABLET, ORAL · Prescription · TE AB
- FANAPT · ILOPERIDONE 4MG · TABLET, ORAL · Prescription · TE AB
- FANAPT · ILOPERIDONE 1MG · TABLET, ORAL · Prescription · TE AB
- FANAPT · ILOPERIDONE 10MG · TABLET, ORAL · Prescription · TE AB
- FANAPT · ILOPERIDONE 6MG · TABLET, ORAL · Prescription · TE AB
- FANAPT · ILOPERIDONE 2MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Iloperidone" as an intervention, any sponsor and status, largest first.
- Relapse Prevention Study in Patients With SchizophreniaPivotal-lookingCompleted
Vanda PharmaceuticalsIndustry
NCT01291511 · 635 participants · Start Feb 2011 · Primary completion Mar 2014
Drug: Iloperidone; Placebo · For: Schizophrenia
Sites: Anaheim, California; Bellflower, California; Costa Mesa, California · 63 sites in all
- Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute SchizophreniaPivotal-lookingCompleted
Vanda PharmaceuticalsIndustry
NCT00254202 · 593 participants · Start Nov 18, 2005 · Primary completion Sep 26, 2006
Drug: Iloperidone; Ziprasidone and 1 more · For: Schizophrenia
Sites: Little Rock, Arkansas; Anaheim, California; Cerritos, California · 42 sites in all
- Switching to Iloperidone From Other Antipsychotics in SchizophreniaPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT01207414 · 501 participants · Start Aug 2010 · Primary completion Jan 2012
Drug: iloperidone · For: Schizophrenia
Sites: Birmingham, Alabama; Cerritos, California; Costa Mesa, California · 59 sites in all
- Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I DisorderPivotal-lookingCompleted
Vanda PharmaceuticalsIndustry
NCT04819776 · 417 participants · Start Mar 22, 2021 · Primary completion Sep 7, 2022
Drug: Iloperidone; Iloperidone Placebo · For: Bipolar I Disorder
Sites: Little Rock, Arkansas; Rogers, Arkansas; Cerritos, California · 27 sites in all
- Randomized Withdrawal Study in Patients With SchizophreniaPivotal-lookingRecruiting
Vanda PharmaceuticalsIndustry
NCT06961968 · 400 participants (planned) · Start May 14, 2025 · Primary completion Nov 2027
Drug: iloperidone; placebo · For: Schizophrenia
Sites: Rogers, Arkansas; Costa Mesa, California; Lemon Grove, California · 22 sites in all
- Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With SchizophreniaPivotal-lookingStatus unknown
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT02453893 · 288 participants (planned) · Start Nov 2013 · Primary completion Jun 2015
Drug: Iloperidone; Risperidone · For: Schizophrenia
Sites: Shanghai, China
- Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat SchizophreniaPivotal-lookingCompleted
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT01623713 · 260 participants · Start Jun 2012 · Primary completion Oct 2013
Drug: iloperidone; Risperidone · For: Schizophrenia; Iloperidone; Efficacy
Sites: Beijing, China
- Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled HypertensionPivotal-lookingRecruiting
Vanda PharmaceuticalsIndustry
NCT07090161 · 240 participants (planned) · Start Sep 15, 2025 · Primary completion Oct 2026
Drug: iloperidone; Placebo · For: Hypertension; Uncontrolled Hypertension
Sites: Phoenix, Arizona; Tempe, Arizona; Tucson, Arizona · 28 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective108
- dizziness107
- insomnia83
- weight increased83
- anxiety70
- fatigue68
- nausea54
- dyskinesia51
- suicidal ideation49
- dyspnoea48
- off label use48
- somnolence48
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2010 | 75 |
| 2011 | 134 |
| 2012 | 393 |
| 2013 | 76 |
| 2014 | 84 |
| 2015 | 64 |
| 2016 | 60 |
| 2017 | 82 |
| 2018 | 76 |
| 2019 | 87 |
| 2020 | 46 |
| 2021 | 49 |
| 2022 | 34 |
| 2023 | 27 |
| 2024 | 28 |
| 2025 | 73 |
| 2026 | 87 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Fanapt (Iloperidone)
2024 spending
$87.3M
Beneficiaries
4,229
41,979 claims
Per beneficiary
$20,648
$42.46 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $80,887,041 |
| 2021 | $90,157,616 |
| 2022 | $94,005,689 |
| 2023 | $92,779,041 |
| 2024 | $87,322,405 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
Leucht S, Cipriani A, Spineli L, et al. · Lancet 2013 · Comparative Study, Meta-Analysis
- Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Leucht S, Crippa A, Siafis S, et al. · Am J Psychiatry 2020 · Meta-Analysis
- Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis.
Siafis S, Wu H, Wang D, et al. · Mol Psychiatry 2023 · Meta-Analysis, Systematic Review
- Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study.
Torres R, Czeisler EL, Chadwick SR, et al. · J Clin Psychiatry 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Antipsychotic-Related Prolactin Changes: A Systematic Review and Dose-Response Meta-analysis.
Lin X, Siafis S, Tian J, et al. · CNS Drugs 2025 · Systematic Review, Meta-Analysis
- Antipsychotic drug dosing and study discontinuation in schizophrenia: A systematic review and dose-response meta-analysis.
Tian J, Siafis S, Lin X, et al. · Eur Neuropsychopharmacol 2025 · Systematic Review, Meta-Analysis
Sponsor: Vanda Pharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.